1.Acute cholecystitis developed immediately after thoracic kyphoplasty: A case report.
Sang Bum AN ; Jiyeon YIM ; Eunjung KIM ; Jae Hyuck SHIN ; Soo Young PARK ; Sang Chul LEE
Korean Journal of Anesthesiology 2012;63(3):266-269
Postoperative acute cholecystitis is a rare complication of orthopaedic surgery and is unrelated to the biliary tract. In particular, in the case of immediate postoperative state after surgery such as kyphoplasty at the thoracic vertebra, symptoms related to inflammation mimic those of abdominal origin, so the diagnosis and the treatment of acute cholecystitis can be delayed leading to a fatal outcome. It is important that physicians should be aware of the postoperative patient's condition in order to make an early diagnosis and determine treatment.
Biliary Tract
;
Cholecystitis, Acute
;
Early Diagnosis
;
Fatal Outcome
;
Hydrazines
;
Inflammation
;
Kyphoplasty
;
Spine
2.Global Estimates of Reported Vaccine-Associated Ischemic Stroke for 1969–2023: A Comprehensive Analysis of the World Health Organization Global Pharmacovigilance Database
Jaehyeong CHO ; Jaeyu PARK ; Hyesu JO ; Yesol YIM ; Ho Geol WOO ; Jiyeon OH ; Dong Keon YON
Journal of Stroke 2024;26(3):463-467
3.Global Estimates of Reported Vaccine-Associated Ischemic Stroke for 1969–2023: A Comprehensive Analysis of the World Health Organization Global Pharmacovigilance Database
Jaehyeong CHO ; Jaeyu PARK ; Hyesu JO ; Yesol YIM ; Ho Geol WOO ; Jiyeon OH ; Dong Keon YON
Journal of Stroke 2024;26(3):463-467
4.Global Estimates of Reported Vaccine-Associated Ischemic Stroke for 1969–2023: A Comprehensive Analysis of the World Health Organization Global Pharmacovigilance Database
Jaehyeong CHO ; Jaeyu PARK ; Hyesu JO ; Yesol YIM ; Ho Geol WOO ; Jiyeon OH ; Dong Keon YON
Journal of Stroke 2024;26(3):463-467
5.Global Estimates of Reported Vaccine-Associated Ischemic Stroke for 1969–2023: A Comprehensive Analysis of the World Health Organization Global Pharmacovigilance Database
Jaehyeong CHO ; Jaeyu PARK ; Hyesu JO ; Yesol YIM ; Ho Geol WOO ; Jiyeon OH ; Dong Keon YON
Journal of Stroke 2024;26(3):463-467
6.Rotational intraperitoneal pressurized aerosol chemotherapy with paclitaxel and cisplatin: pharmacokinetics, tissue concentrations, and toxicities in a pig model
Soo Jin PARK ; Eun Ji LEE ; Aeran SEOL ; Sunwoo PARK ; Jiyeon HAM ; Ga Won YIM ; Seung-Hyuk SHIM ; Whasun LIM ; Suk-Joon CHANG ; Gwonhwa SONG ; Ji Won PARK ; Hee Seung KIM ;
Journal of Gynecologic Oncology 2022;33(5):e56-
Objective:
We used paclitaxel and cisplatin, known to be effective in intraperitoneal chemotherapy, in a novel prototype of rotational intraperitoneal pressurized aerosol chemotherapy (RIPAC) and evaluated the pharmacokinetics, tissue concentrations, and toxicities in a pig model.
Methods:
We developed RIPAC, including the nozzle with the conical pendulum motion, and used 10% of intravenous doses of paclitaxel and cisplatin. We used high-performance liquid chromatography followed by tandem mass spectrometry to analyze serum and tissue concentrations. We applied a non-compartment model to study pharmacokinetics to analyze the time-dependent serum concentrations measured before RIPAC to 48 hours. We evaluated the difference in tissue concentrations between twelve peritoneal regions by the modified peritoneal cancer index. For evaluating toxicities, we observed hepatic and renal function until 4 days after RIPAC.
Results:
Six pigs underwent RIPAC using paclitaxel (n=3) and cisplatin (n=3). The peak serum concentration (Cmax) and the area under the curve were higher for cisplatin, while the time to the peak serum concentration (Tmax) was longer for paclitaxel. Moreover, the parietal peritoneum showed higher tissue concentrations than the visceral peritoneum, and the ratio of tissue to serum concentrations using Cmax was higher for paclitaxel (172.2–6,237.9) than for cisplatin (0.1–9.3). However, there were no renal and hepatic toxicities after RIPAC with paclitaxel or cisplatin.
Conclusion
Delayed absorption of paclitaxel sprayed by RIPAC into the peritoneum to the bloodstream may lead to higher tissue concentrations at different regions and lower serum concentrations than cisplatin.